Thermalin Diabetes Revenue and Competitors

Our new forms of insulin, based on novel protein designs and formulations, will enable insulin-dependent type 1 and type 2 diabetes patients to achieve improved glycemic control and quality of life, while reducing the costs of diabetes-related illnesses to the healthcare system. Our team includes the leading scientist in insulin biochemistry (Professor at Case Western Reserve Medical School), the co-inventor of the first commercial insulin analog, the CEO of the Joslin Diabetes Center in Boston (director), two experienced drug/device deal-makers, and a world-class scientific staff. Our clinical advisory board includes some of the foremost endocrinologists in the country. We plan to be in human testing on our lead compound by the end of 2013, and several major pharmaceutical companies actively follow our science, awaiting first-in-human data, and anticipating the expiry by 2014 of patents on three of the leading insulin analogs. Target product profiles for which we have viable candidates include: - Ultra-stable insulins that do not need to be refrigerated (especially useful in the developing world) - Ultra-rapid absorbing insulins required for artificial pancreas systems - Ultra-concentrated insulins for miniaturized insulin pumps and for insulin-resistant patients - Liver-focused insulins that are ideal for athletically active diabetes patients We are raising an $8M Series B financing that we have good reason to believe will be the last private money before an exit.